MedImmune, the global biologics arm of AstraZeneca, and WuXi AppTec, have formed a joint venture to develop and commercialize MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China. MedImmune will provide technical and development expertise and WuXi AppTec will provide local regulatory, manufacturing and clinical trial support, as the government requires local manufacture of drugs not approved in other markets.    The joint venture will control the development of MEDI5117 ...